MYBL2 and myelodysplastic syndrome: We were unable to implicate aberrant methylation of the MYBL2 genomic locus as an additional mechanism of gene-dosage reduction; instead, we found elevated expression levels of mir-29a and mir-30e, which are known to target MYBL2 (Martinez et al., 2011), in CD34+ cells from patients with MDS and low levels of MYBL2 expression.